Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye

Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation

“…The modification of a BS signal can occur as a function of time and particle migration and is graphically reported in the form of positive (BS increase) or negative peaks (BS decrease). Namely, the migration of particles from the bottom to the top of a sample leads to a progressive concentration decrease at the bottom of the sample and as a consequence a decrease in the BS signal (negative peak) and an increase in the intensity of the T (positive peak) [36,56]. The opposite is true at the top of the sample.…”

“…LNs are heterogeneous systems and thermodynamically unstable, and therefore, they have a significant tendency to lose physical stability during storage [56,57]. Techniques, such as microscopy, spectroscopy, turbidity and particle size analysis, are used to detect destabilization in nanoparticulate systems.…”

Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone

“…Although these methods can achieve high drug concentrations in the posterior segment of the vitreous humor, lens, retina, and other ocular tissues, their broad clinical application is limited by potential complications such as tissue damage, infection and injury, and retinal hemorrhage. [8][9][10][11] Drug administration into the anterior segment has been proposed to circumvent these problems. In intraocular administration, drug molecules must diffuse over a long distance from the site of corneal penetration and penetrate the ocular barrier -which consists of the convection flow of the aqueous humor from the ciliary body to Schlemm's canal, together with lacrimal fluid, blood-aqueous humor, retinal blood, and a corneal avascular component -and be specifically absorbed by the retinal pigment epithelium.…”

Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions

“…A variety of systems have been proposed, based on solid lipid nanoparticles [64,65], polymeric nanoparticles [66,67], liposomes [68], micelles [69] and dendrimers [70,71]. When injected in the vitreous, these nanotherapies allows for prolonged drug release [72,73], which reduces the number of injections required.…”